原文地址
新词汇
| epidemoic |
[ˌepɪˈdemɪk] |
流行病 |
| annex |
[əˈneks] |
附件 |
| Viet Nam |
[viˈɛt næm] |
越南 |
| cumulative |
[ˈkjuːmjələtɪv] |
累计的 |
| hazad |
|
危险、危害 |
正文
Global overview
Globally, during the week of 4 through 10 April 2022, the number of
new COVID-19 cases and deaths has continued to decline for a third
consecutive week, with over 7 million cases and over 22 000 deaths
reported, a decrease of 24% and 18% respectively, as compared to the
previous week (Figure 1).
总的来说，从4月4日~10日的这一周内，新的COVID-19确诊和死亡数已经持续下降了3个星期，共报道了超过700万的病例和22000例死亡，相比于上个星期分别下降了24%和18%
All regions reported decreasing trends in the number of new weekly
cases and deaths (Table 1). As of 10 April 2022, over 496 million
confirmed cases and over 6 million deaths have been reported
globally.
所有区域最近一个星期从上报的数量来说都呈现下降的趋势。截止2022年4月10日，全球共报道超过496万确诊以及超过600万的死亡。
These trends should be interpreted with caution as several countries
are progressively changing their COVID-19 testing strategies, resulting
in lower overall numbers of tests performed and consequently lower
numbers of cases detected.
这个趋势可以谨慎的解释为一些国家正在改变他们的检测策略，导致更低的检测数字，从而导致更低的确诊量
At the country level, the highest numbers of new weekly cases were
reported from the Republic of Korea (1 459 454 new cases; -29%), Germany
(1 019 649 new cases; -26%), France (927 073 new cases; -3%), Viet Nam
(453 647 new cases; -43%), and Italy (447 322 new cases; -8%)
国家的等级上，最新的周确诊量最多的是韩国，德国，法国，越南和意大利
The highest numbers of new weekly deaths were reported from the
United States of America (3 682 new deaths; -9%), Republic of Korea (2
186 new deaths; -6%), the Russian Federation (2 008 new deaths; -15%),
Germany (1 686 new deaths; +6%), and Brazil (1 120 new deaths;
-22%).
死亡数最多的是美国，韩国，俄罗斯联邦，德国，巴西。
Special
Focus: Update on SARS-CoV-2 variants of interest and variants of
concern
WHO, in collaboration with national authorities, institutions and
researchers, routinely assesses if variants of SARSCoV-2 alter
transmission or disease characteristics, or impact effectiveness of
vaccines, therapeutics, diagnostics or public health and social measures
(PHSM) applied to control disease spread. Potential variants of concern
(VOCs), variants of interest (VOIs) or variants under monitoring (VUMs)
are regularly assessed based on the risk posed to global public
health.
WHO，和国家当局、机构、研究者们合作，日常评估是否病毒变种改变传播途径或者病理特性，或影响疫苗、治疗、诊断或者公共卫生以及社会措施控制疾病传播的效用。根据公布的全球公共健康定期评估潜在的病毒变种，感兴趣的变种和监控中的变种。
The classifications of variants will be revised to reflect the
continuous evolution of circulating variants and their changing
epidemiology. Criteria for variant classification, and the current lists
of VOCs, VOIs and VUMs, are available on the WHO Tracking SARS-CoV-2
variants website. National authorities may choose to designate other
variants and are encouraged to investigate and report on the impacts of
these variants. When referring to the genomic sequence of SARS-CoV-2
identified from the first cases (December 2019), the term ‘index virus’
should be used.
变种得分类将会修改，以反应流行变种得持续进化以及他们流行病学的变化。变种分类的标准，当前关注变种，感兴趣的变种，监控中的变种的列表，都可以在WHO变种网站上跟踪查看。国家当局可能选择命名其他变种，他们被鼓励调查和报道其他变种的影响。当参考第一例认证的基因序列时，需要使用“病毒索引”一词
The Omicron variant remains the dominant variant circulating
globally, accounting for nearly all sequences recently reported to
GISAID. Among the 379 278 sequences uploaded to GISAID with specimens
collected in the last 30 days , 376 082 (99.2%) were Omicron, 125
(<0.1%) were Delta and 2 961 (0.8%) sequences were not assigned to a
Pango lineage. These trends should be interpreted with due consideration
of the limitations of surveillance systems, including differences in
sequencing capacity and sampling strategies between countries, as well
as laboratory turnaround times for sequencing and delays in
reporting.
Omicron依旧是世界范围传播的主要变种，在过去的30填收集的379278份序列样本中，几乎所有序列都是Omicron
，其中376082份是Omicron
，125份是Delta，另外2961份未分具体类系。这个趋势可以解释为监测系统的局限性，包括国家之间测序的能力，采样策略的区别等，以及实验室测序和报告延迟的周转时间。
WHO continues to monitor several descendent lineages under the
Omicron VOC, including BA.1, BA.2, BA.3 as well as now BA.4 and BA.5 .
It also includes BA.1/BA.2 circulating recombinant forms, such as XE.
The full list can be found here
https://cov-lineages.org/lineage_list.html
WHO持续监控几个OMicron世系下的后代，包括。。。。。也包括循环重组格式的。。。。。所有的列表能在这里找到。
A small number of sequences of BA.4 and BA.5 descendent lineages have
now been detected in a few countries. Both have additional mutations in
the Spike region (S:L452R, S:F486V) and unique mutations outside of
Spike. The S:L452R and S:F486V mutations are associated with potential
immune escape characteristics. In addition, the majority of BA.4 and
BA.5 sequences have the 69-70 deletion responsible for S gene target
failure (SGTF) in some PCR assays. This may prove useful for
surveillance purposes in places where BA.2 is dominant, as the 69-70
deletion is largely not present in BA.2 sequences.
某个分支的后代的序列在几个国家被检测到。都含有额外的突触突变和特别的外部突触。这些突变与潜在的免疫力逃逸特征有关联。
这应该可以证明有助于监测这几处。
WHO is working with scientists to further assess the characteristics
of these lineages and their public health implications. WHO recommends
countries to continue surveillance, where possible, and rapid data
sharing on publicly available databases.
WHO整与科学家们合作评估这些世系的特性以及他们对于公共健康的影响。WHO建议各个国家持续监测，如果可能的话，快速分享数据。
Special
Focus: Update on WHO COVID-19 global rapid risk assessment
The COVID-19 pandemic continues to evolve, as does our understanding
of the SARS-CoV-2 virus, and the response needed to control its spread
and impact. In WHO’s most recent rapid risk assessment, which was
completed on 6 April 2021, the global public health risk was assessed to
remain very high due to the ongoing risks to human health, risk of
spread and risk of insufficient control capacities. Under the Emergency
Response Framework, WHO undertakes risk assessments and situation
analyses on a regular basis to inform its response to emerging
situations. In addition, WHO periodically reviews the current risk
status of public health events through an in-depth hazard, exposure and
context assessment. This also includes a review of the vulnerabilities
and capacities available to respond to the public health event and to
investigate the current risk to human health, risks of ongoing spread
globally, and risk of insufficient control capacities. Such assessments
are used as an internal WHO decision-making tool, and to support
independent deliberations, including but not limited to meetings of the
International Health Regulations (IHR 2005) Emergency Committee
regarding the COVID-19 pandemic.
To date, 13 global rapid risk assessments have been undertaken for
COVID-19, and additional assessments have been conducted for specific
events, such as the emergence of SARS-CoV-2 variants. Here, we provide a
synopsis of the most recent in-depth global rapid risk assessment for
COVID-19.
Despite a reduction in SARS-CoV-2 testing observed since the
beginning of 2022 in many Member States, the COVID-19 pandemic continues
with intense transmission and high levels of death primarily among
unvaccinated at-risk populations. The highly transmissible Omicron
variant of concern has rapidly replaced all other circulating variants
in almost all countries in which it has been reported, and has become
dominant globally.
Omicron’s properties of immune escape have been associated with the
rapid and almost synchronous increase in the global incidence of
COVID-19 cases reported until the end of January 2022. A further
increase observed at the beginning of March was driven primarily by a
delayed increase in case incidence in the Western Pacific Region and a
rebound in the number of new cases reported in the European Region. This
trend was likely due to a combination of factors, including the
predominance of the Omicron Pango lineages BA.1, and then BA.2, with a
transmission advantage over other Omicron lineages; relaxation of public
health and social measures (PHSM); and waning of humoral immunity
following vaccination and/or prior infection. The recent detection of
emerging recombinants of the Delta-Omicron and Omicron descendent
lineages requires ongoing close monitoring.
Unlike previous waves, the most recent wave due to Omicron can be
characterized by a decoupling between the number of cases,
hospitalizations (particularly for intensive care) and deaths in many
countries. However, data continue to show that those who are
unvaccinated remain at higher risk of severe disease following infection
with Omicron as compared to those who have been vaccinated. Despite the
reduction in severity, the massive increases 7 in cases with Omicron
have led to large numbers of hospitalizations, putting further pressure
on healthcare systems, and in some countries, similar or higher numbers
of deaths when compared to previous peaks.
While vaccine effectiveness (VE) wanes against Omicron for all
disease outcomes as compared to other VOCs following the primary
vaccination series, VE estimates for Omicron remain the highest for
severe disease. Furthermore, there is evidence that a booster dose
substantially improves VE for all outcomes; however, more data are
needed to characterize the duration of this protection.
Over 11 billion vaccine doses have been distributed globally.
Nevertheless, substantial inequities remain, with only 11% of those in
low-income countries (LICs) having completed the primary series; and
major differences among regions, with vaccination coverage ranging from
82% in the Western Pacific Region to 13% in the African Region. There is
particular concern about reaching the most vulnerable populations who
remain unvaccinated, particularly those of older age and those with
comorbidities. Globally, an estimated 35% of those aged 60 years and
over are awaiting completion of the primary vaccination series. Despite
low vaccination coverage in the African Region, the most recent
estimates of combined seroprevalence (vaccine and infection-derived
humoral immune response) were 72.6% (95% CI: 71.7-73.5%). Considering
the low vaccine coverage, such seroprevalence estimates highlight the
extent of SARS-CoV-2 transmission across the Region. WHO Emergency Use
Listing (EUL) approved diagnostic tests, including nucleic acid
amplification tests (e.g. polymerase chain reaction (PCR) assays) with
more than one viral target or antigen-detection rapid diagnostic tests
(Ag-RDTs), remain effective at detecting Omicron infection, including
BA.1 and BA.2. WHO is concerned that during recent months, some
countries have significantly reduced SARS-CoV-2 testing, despite
widespread availability of diagnostic tests. Unless robust surveillance
systems are retained, countries may lose the ability to accurately
interpret epidemiological trends, implement the appropriate measures
necessary to reduce transmission and monitor and assess the evolution of
the virus.
Despite current high rates of transmission of SARS-CoV-2, many
countries have dropped most PHSM without following a layered or staged
approach to relaxation. This can lead to the erosion of public trust and
PHSM may not be easily re-implemented should the future need arise, for
example following the emergence of a new VOC. Each country faces
different circumstances based on the epidemiological situation and the
context. WHO has published an updated Strategic Preparedness, Readiness
and Response Plan to End the Global COVID-19 Emergency in 2022 which
outlines future scenarios of COVID-19 and how the current strategy needs
to be adjusted taking into account the difficulties posed by the
pandemic in the light of the many other public health and global
challenges. This is particularly apparent during other emergencies
including the war in Ukraine and protracted conflicts in many other
countries.
The confidence in the available information on the global public
health risk remains moderate. There are still gaps in knowledge about
the phenotypic impact of emerging SARS-CoV-2 variants and recombinants;
the long-term duration of infection and vaccine-derived protection,
particularly against severe disease and hospitalization; and the impact
of lifting and changing PHSM on transmission, hospitalization and
mortality.
